Non-Invasive CGM Patch
Diabetes Management (Type 1, Type 2, Pre-diabetes)
Pre-clinicalActive
Key Facts
Indication
Diabetes Management (Type 1, Type 2, Pre-diabetes)
Phase
Pre-clinical
Status
Active
Company
About Transdermal Diagnostics
Transdermal Diagnostics, founded in 2016 as a UK MedTech spin-out, is developing a disruptive, needle-free CGM system. Its patented platform utilizes reverse iontophoresis via hair follicles to sample interstitial fluid, coupled with an array of electrochemical sensors for calibration-free measurement. The company is pre-revenue and has secured non-dilutive grant funding and a pre-seed investment round to advance its first product towards clinical validation. Its mission is to transform chronic disease management, starting with diabetes, by improving user adherence and accessibility through a pain-free wearable.
View full company profile